Table 2.
Patient characteristics after propensity score matching
| Total | No hyperuricemia | Hyperuricemia, treated | Hyperuricemia, untreated | P‐value | |
|---|---|---|---|---|---|
| No. of patients | 1194 | 398 | 398 | 398 | |
| Age | 73 (65; 80) | 73 (65; 79) | 73 (65; 81) | 73 (65; 80) | .641 |
| Sex: woman | 441 (36.9%) | 147 (36.9%) | 147 (36.9%) | 147 (36.9%) | 1.000 |
| BMI | 29 (26; 33) | 29 (26; 33) | 29 (26; 33) | 29 (26; 32) | .742 |
| SBP | 140 (115; 160) | 135 (115; 160) | 140 (120; 160) | 140 (111; 160) | .609 |
| EF (%) | 35 (25; 47) | 35 (25; 45) | 35 (25; 50) | 35 (25; 50) | .553 |
| eGFR (CKDEPI) | 46 (34; 61) | 48 (36; 61) | 46 (32; 62) | 43 (33; 59) | .075 |
| Hemoglobin (g/L) | 132 (116; 145) | 132 (116; 145) | 131 (116; 145) | 132 (117; 144) | .990 |
| Uric acid (μmol/L) | 468 (372; 565) | 389 (322; 444) | 484 (373; 601) | 560 (519; 625) | <.001 |
| NT‐proBNP (pg/mL) | 5537 (2740; 10 915) | 4867 (2402; 12 036) | 4993 (3083; 8776) | 6323 (2883; 11 918) | .642 |
| Killip class – III + IV | 328 (27.5%) | 115 (28.9%) | 100 (25.1%) | 113 (28.4%) | .435 |
| Atrial fibrillation | 390 (32.7%) | 125 (31.4%) | 140 (35.2%) | 125 (31.4%) | .435 |
| Diabetes mellitus | 618 (51.8%) | 199 (50.0%) | 212 (53.3%) | 207 (52.0%) | .658 |
| History of CAD | 679 (56.9%) | 225 (56.5%) | 224 (56.3%) | 230 (57.8%) | .904 |
| ACEIs/ARBs | 986 (82.6%) | 330 (82.9%) | 334 (83.9%) | 322 (80.9%) | .523 |
| Beta‐blockers | 993 (83.2%) | 337 (84.7%) | 331 (83.2%) | 325 (81.7%) | .550 |
| Diuretics | 1106 (92.6%) | 366 (92.0%) | 371 (93.2%) | 369 (92.7%) | .809 |
Note: Continuous variables are described by median values (IQR); categorical variables are described by absolute and relative frequencies. P‐value of Kruskal‐Wallis test for continuous variables and P‐value of the Fisher's exact test for categorical variables are reported for the comparison of patient characteristics according to the presence of hyperuricemia and its treatment. NT‐proBNP levels were only available in about 30% of patients.
Abbreviations: ACEIs, angiotensin‐converting enzyme inhibitors, ARBs, angiotensin receptor blockers, BMI, body mass index, CAD, coronary artery disease, EF, ejection fraction, eGFR, estimated glomerular filtration rate, SBP, systolic blood pressure.
P values of less than 0.05 (in bold) are statistically significant.